Jubilant Life Sciences shares surged 6 per cent on Monday, following the Noida-based pharma company's announcement about US regulator's approval for Levetiracetam injection, used in the treatment of epilepsy.
Approval for the Levetiracetam injection will generate incremental revenue for the company, analysts said.
With this approval, Jubilant Life Sciences' total Abbreviated New Drug Application (ANDA) approvals rose to 517 in various regions globally, the company said.
Jubilant Life Sciences shares closed 4.29 per cent higher at Rs 368.1 apiece compared to 0.24 per cent fall in the broader Sensex.
Jubilant Life Sciences shares surged 6 per cent on Monday, following the Noida-based pharma company's announcement about US regulator's approval for Levetiracetam injection, used in the treatment of epilepsy.
Approval for the Levetiracetam injection will generate incremental revenue for the company, analysts said.
With this approval, Jubilant Life Sciences' total Abbreviated New Drug Application (ANDA) approvals rose to 517 in various regions globally, the company said.
Jubilant Life Sciences shares closed 4.29 per cent higher at Rs 368.1 apiece compared to 0.24 per cent fall in the broader Sensex.
Sign Up with Google
RECOMMENDED FOR YOU
POPULAR